1 – 10 of 210
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2026
-
Mark
Survival in mantle cell lymphoma patients burdened by a second primary malignancy
- Contribution to journal › Article
-
Mark
Feasibility of patient-reported outcomes collection in clinical routine at a radiotherapy department
- Contribution to journal › Article
-
Mark
Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma : a pooled analysis of six randomized phase III trials, 1996-2020
- Contribution to journal › Article
-
Mark
Circulating CAR T-Cells After Treatment With Axicabtagene Ciloleucel in Patients With Relapsed/Refractory Aggressive B-Cell Lymphomas and Its Association to Treatment Outcome
- Contribution to journal › Article
-
Mark
Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma
- Contribution to journal › Article
-
Mark
No association between temozolomide maintenance and survival after first-line treatment in primary CNS lymphoma
- Contribution to journal › Debate/Note/Editorial
-
Mark
Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma
- Contribution to journal › Article
- 2025
-
Mark
Circulating tumor DNA determinants of response and outcome in relapsed/refractory mantle cell lymphoma
- Contribution to journal › Article
-
Mark
Validation of POD24 as a robust early clinical indicator of poor survival in mantle cell lymphoma from 1280 patients on clinical trials, a LYSA study
- Contribution to journal › Article
-
Mark
Peripheral T- and natural killer-cell lymphomas : ESMO–EHA Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
- Contribution to journal › Article
